Literature DB >> 24145957

Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?

Frauke Zipp1, Ralf Gold2, Heinz Wiendl3.   

Abstract

IMPORTANCE: Although multiple sclerosis (MS) has long been considered the prototype for an inflammatory, demyelinating disease of the central nervous system, modern histopathology and imaging techniques show that significant damage to neuronal structures already start occurring in the earliest stages of the disease. As the disease progresses, the extent of neuronal pathology accumulates. Therapeutic progress in terms of the prevention of increased disability has only just begun.
OBJECTIVE: To review possible diagnostic improvements of neuronal compartment pathology as well as direct therapeutic interventions based on reports from the last decade and outline clinical results from studies and perspectives on the progression of MS. EVIDENCE REVIEW: Literature search focused on publications and the references contained therein, relating to neuronal compartment pathology and direct therapeutic interventions published in the last decade in well-established peer-reviewed journals. The quality of the cited works was ensured by their acceptance by peer review, participation in clinical trials, and authors' own expert assessment.
FINDINGS: Current MS therapies as well as medications that are in late phase 3 trials or under approval exhibit primarily anti-inflammatory properties. However, clinical and imaging data demonstrate the potential of using novel therapies to prevent neuronal damage. Whether these exhibit effects on the neuronal compartment due to interference with the immune system or additional direct effects depends without question on the specific mechanism of action. CONCLUSIONS AND RELEVANCE: Combining anti-inflammatory and direct neuroprotective, neuroregenerative/repair therapy strategies may open up new avenues in the treatment of MS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145957     DOI: 10.1001/jamaneurol.2013.4391

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  12 in total

Review 1.  [Prognostic and predictively relevant factors for multiple sclerosis].

Authors:  B Tackenberg; T Schneider-Hohendorf; A Müller; J Schodrowski; H Wiendl
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

Review 2.  Revisiting the Mechanisms of CNS Immune Privilege.

Authors:  Antoine Louveau; Tajie H Harris; Jonathan Kipnis
Journal:  Trends Immunol       Date:  2015-10       Impact factor: 16.687

3.  Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis.

Authors:  Pierre Kolber; Swantje Montag; Vinzenz Fleischer; Felix Luessi; Janine Wilting; Joachim Gawehn; Adriane Gröger; Frauke Zipp
Journal:  J Neurol       Date:  2015-04-11       Impact factor: 4.849

4.  Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Authors:  Caspar B Seitz; Amgad Droby; Lena Zaubitzer; Julia Krämer; Mathieu Paradis; Luisa Klotz; Heinz Wiendl; Sergiu Groppa; Sven G Meuth; Frauke Zipp; Vinzenz Fleischer
Journal:  J Neurol       Date:  2018-08-02       Impact factor: 4.849

5.  Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex.

Authors:  René-Maxime Gracien; Sarah C Reitz; Stephanie Michelle Hof; Vinzenz Fleischer; Hilga Zimmermann; Amgad Droby; Helmuth Steinmetz; Frauke Zipp; Ralf Deichmann; Johannes C Klein
Journal:  Eur Radiol       Date:  2015-10-22       Impact factor: 5.315

Review 6.  Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").

Authors:  Heinz Wiendl; Christian Elger; Hans Förstl; Hans-Peter Hartung; Wolfgang Oertel; Heinz Reichmann; Stefan Schwab
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

7.  Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS.

Authors:  Muthuraman Muthuraman; Vinzenz Fleischer; Pierre Kolber; Felix Luessi; Frauke Zipp; Sergiu Groppa
Journal:  Front Neurosci       Date:  2016-02-02       Impact factor: 4.677

8.  Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis.

Authors:  Vinzenz Fleischer; Nabin Koirala; Amgad Droby; René-Maxime Gracien; Ralf Deichmann; Ulf Ziemann; Sven G Meuth; Muthuraman Muthuraman; Frauke Zipp; Sergiu Groppa
Journal:  Ther Adv Neurol Disord       Date:  2019-04-24       Impact factor: 6.570

9.  Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis.

Authors:  Dumitru Ciolac; Felix Luessi; Gabriel Gonzalez-Escamilla; Nabin Koirala; Christian Riedel; Vinzenz Fleischer; Stefan Bittner; Julia Krämer; Sven G Meuth; Muthuraman Muthuraman; Sergiu Groppa
Journal:  Front Immunol       Date:  2019-07-30       Impact factor: 7.561

10.  Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic.

Authors:  Sharon W Way; Joseph R Podojil; Benjamin L Clayton; Anita Zaremba; Tassie L Collins; Rejani B Kunjamma; Andrew P Robinson; Pedro Brugarolas; Robert H Miller; Stephen D Miller; Brian Popko
Journal:  Nat Commun       Date:  2015-03-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.